Biora Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Adi Mohanty

Chief Executive Officer (CEO)

US$3.1m

Compensación total

Porcentaje del salario del CEO	18.3%
Permanencia del CEO	3yrs
Participación del CEO	0.6%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adi Mohanty en comparación con los beneficios de Biora Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$87m
Mar 31 2024	n/a	n/a	-US$111m
Dec 31 2023	US$3m	US$574k	-US$124m
Sep 30 2023	n/a	n/a	-US$122m
Jun 30 2023	n/a	n/a	-US$64m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$4m	US$550k	-US$49m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$140m
Mar 31 2022	n/a	n/a	-US$176m
Dec 31 2021	US$10m	US$63k	-US$179m

Compensación vs. Mercado: La compensación total de Adi($USD3.14M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD490.17K).

Compensación vs. Ingresos: La compensación de Adi ha sido consistente con los resultados de la empresa en el último año.

CEO

Adi Mohanty (57 yo)

3yrs

Permanencia

US$3,139,017

Compensación

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Aditya Mohanty	CEO & Director	3yrs	US$3.14m	0.63% € 62.4k
Eric d'Esparbes	Chief Financial Officer	5.5yrs	US$1.60m	0.23% € 23.3k
Clarke Neumann	Senior VP	10.2yrs	US$1.53m	0.21% € 21.1k
Robyn Hatton	Head of Human Resources	no data	sin datos	sin datos
Kevin Howe	Senior VP of Strategic Operations	no data	sin datos	sin datos
Sharat Singh	Head of Research	2.6yrs	sin datos	sin datos
Paul Shabram	Head of Technical Operations	2.6yrs	sin datos	sin datos
Ariella Kelman	Chief Medical Officer	1.5yrs	sin datos	sin datos
James Knight	Head of Business Development	less than a year	sin datos	sin datos

2.6yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4ZU se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Aditya Mohanty	CEO & Director	3yrs	US$3.14m	0.63% € 62.4k
Brian Kotzin	Independent Director	5.4yrs	US$185.11k	0.050% € 4.9k
William Chey	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	sin datos	sin datos
Anthony Lembo	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	sin datos	sin datos
Geert D'Haens	Member of Inflammatory Bowel Disease Clinical Advisory Board	3.4yrs	sin datos	sin datos
Bruce Sands	Chairman of Inflammatory Bowel Disease Clinical Advisory Board	3.4yrs	sin datos	sin datos
Jeffrey Alter	Independent Chairman	5.8yrs	US$208.11k	0.052% € 5.2k
Mark Pimentel	Member of Clinical Advisory Board - SIBO & Functional Bowel Disorders	no data	sin datos	sin datos
Lynne Powell	Independent Director	5.8yrs	US$163.11k	0.049% € 4.9k
Severine Vermeire	Member of Inflammatory Bowel Disease Clinical Advisory Board	3.4yrs	sin datos	sin datos
Jill Howe	Independent Director	3yrs	US$180.11k	0.049% € 4.8k
Satish Rao	Chair of Clinical Advisory Board-SIBO/Functional Bowel Disorders	no data	sin datos	sin datos

3.4yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 4ZU se considera experimentada (3.4 años de antigüedad promedio).

Biora Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics, Inc. Announces Board Appointment

Recent updates

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000002 million.

Athyrium Capital Engages in Discussions with Biora Therapeutics

Biora Therapeutics Announces Positive Nasdaq Listing Decision

Athyrium Capital Management Engages with Biora Therapeutics

Second quarter 2024 earnings released: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023)

Biora Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Biora Therapeutics, Inc. Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented At KOL Event

Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc

Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600

Biora Therapeutics Provides Non-Compliance Update

Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director

First quarter 2024 earnings released: US$0.14 loss per share (vs US$1.59 loss in 1Q 2023)

Biora Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of BT-600

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Full year 2023 earnings released: US$7.88 loss per share (vs US$6.40 loss in FY 2022)

Biora Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose (Sad) Cohorts of Phase 1 Clinical Study of BT-600

Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Third quarter 2023 earnings released: US$4.89 loss per share (vs US$1.99 loss in 3Q 2022)

Biora Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Biora Therapeutics Presents Data on the Biojet™ Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Biora Therapeutics, Inc. (NasdaqGM:BIOR) acquired Interface Therapeutics Inc.

Biora Therapeutics Progresses Its BioJet™ Systemic Oral Delivery Platform

New major risk - Financial position

First half 2023 earnings released: US$3.01 loss per share (vs US$2.79 loss in 1H 2022)

Biora Therapeutics, Inc. Announces New Patents Covering Its BioJet Systemic Oral Delivery Platform

Biora Therapeutics, Inc. Announces Clinical Device Performance Study Results for its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

An unknown large diagnostics company acquired Legacy Diagnostics Assets of Biora Therapeutics, Inc. (NasdaqGM:BIOR).

High number of new and inexperienced directors

Biora Therapeutics Announces New Patents for Its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

Biora Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Biora Therapeutics Announces Improved Bioavailability Results for Its Systemic Delivery Platform

Biora Therapeutics Receives Compliance Letter from Nasdaq

Biora Therapeutics, Inc. Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

Biora Therapeutics, Inc. Receives Feedback from the United States Food and Drug Administration on Its Clinical Development Plans for Its Pgn-600 Program

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Athyrium Capital Engages in Discussions with Biora Therapeutics

Third quarter 2022 earnings released: US$0.08 loss per share (vs US$0.39 loss in 3Q 2021)

High number of new and inexperienced directors

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering.

Biora Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biora Therapeutics, Inc. Shares Data from Device Performance Study in Ulcerative Colitis Patients

Biora Therapeutics, Inc. Shares Preclinical Data on Oral Delivery of Biologics At the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics, Inc. Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. Announces Board Appointment

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.30 loss in 1Q 2021)

Biora Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Full year 2021 earnings released: US$1.86 loss per share (vs US$7.01 loss in FY 2020)

Progenity, Inc. Announces Departure of Damon Silvestry

Progenity, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Progenity, Inc.(NasdaqGM:PROG) dropped from Russell 2500 Growth Index

Análisis de compensación del CEO